Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07233096

Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors

Conditions: Liver Transplantation, Living Donor, Postoperative Pain

Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 64
Sponsor: Istinye University

Location: istinye University Istanbul

Summary

Postoperative pain control plays a crucial role in enhancing recovery and improving early mobilization in living liver donors. The rectus-intercostal fascial plane (RIFP) block is a novel ultrasound-guided regional anesthesia technique that provides anterior abdominal wall analgesia by targeting the intercostal nerves between the rectus abdominis and intercostal muscle fascia. This prospective, randomized controlled clinical study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effects of the RIFP block compared with standard intravenous analgesia in living liver donors undergoing donor hepatectomy. Participants will be randomly assigned to two groups: Group 1 (RIFP Block): Patients receiving an ultrasound-guided rectus-intercostal fascial plane block using 20 mL of 0.25% bupivacaine at the end of surgery, in addition to standard IV PCA (morphine). Group 2 (Control): Patients receiving only standard IV PCA (morphine) without regional block.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 75 years * Patients with American Society of Anesthesiology (ASA) physical status I-II * Patients scheduled for a living donor hepatectomy Exclusion Criteria: * Allergy to local anesthetics * Coagulopathy * Skin infection at the block area * Advanced renal failure * Chronic pain syndromes * Alcohol or drug abuse * Psychiatric disorders

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07233096). StuddyBuddy aggregates publicly available trial information.